Sign up to attend Olink's lunch session "Advancing Precision Medicine: Prognostic Biomarkers for Pediatric Crohn's Disease" at US Hupo 2022.
Prognostic biomarkers are measurable indicators that provide information about how a disease will progress over time. At present, due to a relative lack of available prognostic biomarkers, it is difficult to predict long-term outcomes in patients with pediatric Crohn’s disease. A test that would provide information regarding the probability that a given patient would later experience major debilitating intestinal complications of pediatric Crohn’s disease, like fibrostenosis and fistulas, could be an important tool to optimize care, particularly for vulnerable pediatric patients.
Multiple technologies have been explored for this purpose, however, there is still a need to identify and validate improved prognostic biomarkers to advance precision medicine for inflammatory bowel diseases like Crohn’s disease. One approach that has generated significant enthusiasm is the use of analytically validated high-throughput proteomics platforms developed by Olink Proteomics. The Olink Proximity Extension Assay (PEA) platform is analytically validated for high-throughput and provides highly sensitive quantitation of over 1,000 protein markers; the platform is relatively cost-effective; and development of custom assays is available, including regulatory-grade validation.
This session will discuss findings related to the identification, using machine learning, of prognostic mRNA-based and protein-based biomarkers able to identify pediatric patients at high risk of developing complications with a high degree of accuracy at diagnosis.
Andres Hurtado-Lorenzo, Ph.D.
Vice President, Translational Research at Crohn's & Colitis Foundation
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.